Memantine Grindeks (Memantine Hydrochloride)

Memantine acts as a non‑competitive antagonist at NMDA receptors, blocking excessive calcium influx caused by over‑activation of glutamate pathways. This moderates excitotoxicity while allowing normal synaptic transmission, which can help preserve neuronal function in Alzheimer’s disease.

The dosage of Memantine Grindeks is determined by the prescribing clinician based on the patient’s condition, renal function, and tolerability. The prescriber will set the appropriate dose and titration schedule.

Safety of memantine in pregnancy and lactation has not been fully established. Healthcare providers should consider the potential benefits against possible risks and discuss options with the patient before prescribing.

To request Memantine Grindeks, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Memantine belongs to the NMDA‑receptor antagonist class, whereas other approved agents such as donepezil or rivastigmine are acetylcholinesterase inhibitors. Memantine is typically used in moderate to severe stages and may be combined with an inhibitor for additive benefit, while the others are often started earlier in the disease course.

Store Memantine Grindeks at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains intact until use.

Memantine Grindeks is taken orally, usually once daily after a meal to improve absorption and reduce gastrointestinal discomfort. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include severe allergic reactions such as anaphylaxis, skin conditions like Stevens‑Johnson syndrome, seizures, and cardiac arrhythmias. Patients should seek immediate medical attention if they experience rash, difficulty breathing, sudden weakness, or irregular heartbeats.

Memantine Grindeks is contraindicated in patients with known hypersensitivity to memantine or any of its excipients. Caution is advised for individuals with severe renal impairment, uncontrolled epilepsy, or those taking other NMDA antagonists, as the risk of adverse effects may be higher.